Breakthroughs in AML: Investigational Therapies and Emerging Targets
Subject-matter experts highlight unmet needs in AML treatment, investigational therapies, and emerging targets showcased in recent studies.
EP: 1.MDS Diagnosis and Risk Stratification
EP: 2.Tailoring Treatment Approaches for Patients with MDS
EP: 3.Advancing MDS Care: Novel Therapies and Recent Updates
EP: 4.Factors Influencing Treatment Selection in Patients with MPNs
EP: 5.Innovations in MPN Therapy: Ongoing Trials and Latest Findings
EP: 6.Diagnosis, Biomarker Testing, and Optimizing Treatment Selection for Patients with AML
EP: 7.Breakthroughs in AML: Investigational Therapies and Emerging Targets
EP: 8.Understanding the Role of Allogeneic Transplants in Patient Care
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
